Company now enrolling patients at leading research centers in Canada as well as in the United States LONDON, May 17, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held ...
- Company has achieved 50 percent of target enrollment in global Phase 3 trial The REACH-CDM trial will enroll a total of 56 patients. Upon completion of the trial, patients will have the opportunity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback